Results 61 to 70 of about 206,755 (278)
Platelet refractoriness – practical approaches and ongoing dilemmas in patient management
Platelet refractoriness can represent a significant clinical problem that complicates the provision of platelet transfusions, is associated with adverse clinical outcomes and increases health care costs.
Judith Marsh +7 more
core +1 more source
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo +10 more
wiley +1 more source
Platelet transfusions have contributed to the revolutionary modern treatment of hypoproliferative thrombocytopenia. Despite the long-term application of platelet transfusion in therapeutics, all aspects of their optimal use (i.e., in cases of ABO and/or ...
Serena Valsami +4 more
doaj +1 more source
Diabetic bone defects remain a critical clinical challenge. A 3D‐printed BCPG‐MF@Y scaffold, embedding Yoda1‐functionalized manganese dioxide‐ferritin nanozymes, scavenges mtROS, suppresses the cGAS–STING pathway, and reverses cellular senescence, while Yoda1 activates Piezo1 to direct BMSCs fate to synergistically reprogram the osteoimmune ...
Qing‐Song Deng +16 more
wiley +1 more source
Platelet Transfusion Refractoriness
Platelet transfusion has been used for decades as a highly beneficial therapeutic measure to prevent or stop bleeding in patients with severe thrombocytopenia by increasing the circulatory platelet numbers.
Mortazavi, Reza; id_orcid
core +1 more source
INTRODUCTION: For many years, platelet concentrates have been used for the prevention as well as treatment of bleeding disorders, especially in those patients with haematological problems involving platelet disorders as well as refractoriness, In ...
Nancy Wanjiru Thuku +2 more
doaj +1 more source
Key Points Eight weekly transfusions of F-LR + pathogen-reduced donor platelets were accepted by 31 of 32 (97%) recipient dogs. Among accepting recipients, none developed lymphocyte and only 2 had platelet antibodies not associated with ...
S. Lawrence Bailey +8 more
core +1 more source
Cellular Mechanisms Enabling Mitochondria Transfer and Transplantation
Mitochondrial transfer and transplantation (mitoTT) is examined as a multistep process governed by distinct transfer routes and post‐transfer checkpoints. Mechanisms controlling mitochondrial uptake, network integration, cristae remodeling, mtDNA maintenance, immune sensing, and quality control are highlighted, revealing key biological and ...
F. Seyma Gokdemir +3 more
wiley +1 more source
(A) Establishment and characterization of the osteosarcoma‐targeted dual‐delivery nanoplatform mBAP1/siENO1@LNP‐OTP for simultaneous regulation of BAP1 and ENO1 in tumor cells. (B) After intravenous administration, mBAP1/siENO1@LNP‐OTP preferentially accumulates at tumor sites through OTP‐mediated targeting.
Yechao Shen +13 more
wiley +1 more source
Platelet desialylation, apoptosis, and T-lymphocyte-mediated immune dysregulation: unveiling the pathways of platelet clearance in platelet transfusion refractoriness. [PDF]
Background: Platelet transfusion refractoriness (PTR) is a clinical challenge that can be classified into nonimmunologic and immunologic types, the latter resulting from both platelet alloimmunization and autoimmunity.
Zhou Y +8 more
europepmc +2 more sources

